Immodulon Therapeutics bolsters senior team

Independent biopharmaceutical company Immodulon Therapeutics has appointed Dr Jerome Zeldis as its executive vice chairman.

Prior to his new role, Dr Zeldis served as chief medical officer for Celgene and he also held the role of chief executive officer for Celgene Global Health, gaining expertise in clinical research, medical affairs and drug safety.

He said: “I am particularly pleased to be joining Immodulon, which I see as one of the most exciting biopharmaceutical players in the industry.”

Also joining from Celgene is Dr Graham Burton (pictured right), who previously served the pharma group as its senior vice president of regulatory, pharmacovigilance and clinical quality and has over 30 years’ experience in the pharmaceutical industry. At Immodulon he takes up the roles of chief operating officer.

Hugo Mackenzie Smith, board director, Immodulon Therapeutics, said: “I have no doubt that Jerry and Graham’s wealth of experience and impressive track record at Celgene will support the progression of the continued clinical development and commercialisation of Immodulon’s lead immunotherapy compound IMM-101”.